1
|
Desmares A, Bouzy S, Thonier F, Goustille J, Llamas-Gutierrez F, Genevieve F, Cottin L, Baseggio L, Lemaire P, Lafon CL, Cornillet-Lefebvre P, Galoisy AC, Brouzes C, Rault E, Dindinaud E, Fleury C, Blanc-Jouvan F, Wuilleme S, Bardet V, Fest T, Lamy T, Roussel M, Pannetier M, Pastoret C. Hepatosplenic T-cell lymphoma displays an original oyster-shell cytological pattern and a distinct genomic profile from that of gamma-delta T-cell large granular lymphocytic leukemia. Haematologica 2024. [PMID: 38268478 DOI: 10.3324/haematol.2023.283856] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Indexed: 01/26/2024] Open
Abstract
Not available.
Collapse
Affiliation(s)
- Anne Desmares
- Centre Hospitalier Universitaire de Rennes, Laboratoire d'Hématologie, Rennes, France; Groupe Francophone d'Hématologie Cellulaire, Bron
| | - Simon Bouzy
- Groupe Francophone d'Hématologie Cellulaire, Bron, France; Centre Hospitalier Universitaire de Nantes, Laboratoire d'Hématologie, Nantes
| | | | - Julien Goustille
- Groupe Francophone d'Hématologie Cellulaire, Bron, France; Centre Hospitalier de Saint-Malo, Laboratoire de Biologie, Saint-Malo
| | | | - Franck Genevieve
- Groupe Francophone d'Hématologie Cellulaire, Bron, France; Centre Hospitalier Universitaire d'Angers, Laboratoire d'Hématologie, Angers
| | - Laurane Cottin
- Groupe Francophone d'Hématologie Cellulaire, Bron, France; Centre Hospitalier Universitaire d'Angers, Laboratoire d'Hématologie, Angers
| | - Lucile Baseggio
- Groupe Francophone d'Hématologie Cellulaire, Bron, France; Hospices Civils de Lyon - HCL, Laboratoire d'Hématologie, Bron
| | - Pierre Lemaire
- Groupe Francophone d'Hématologie Cellulaire, Bron, France; Hôpital Saint-Louis AP-HP, Laboratoire d'hématologie, Paris
| | - Carinne Lecoq Lafon
- Groupe Francophone d'Hématologie Cellulaire, Bron, France; Centre Hospitalier Universitaire de Reims, Laboratoire d'hématologie, Reims France
| | | | - Anne-Cécile Galoisy
- Groupe Francophone d'Hématologie Cellulaire, Bron, France; Centre Hospitalier Universitaire de Strasbourg, Laboratoire d'Hématologie, Strasbourg
| | - Chantal Brouzes
- Groupe Francophone d'Hématologie Cellulaire, Bron, France; Hôpital Necker AP-HP, Laboratoire d'hématologie, Paris
| | - Emmanuelle Rault
- Groupe Francophone d'Hématologie Cellulaire, Bron, France; Centre Hospitalier Universitaire de Tours, Laboratoire d'Hématologie, Tours
| | - Elodie Dindinaud
- Groupe Francophone d'Hématologie Cellulaire, Bron, France; Centre Hospitalier Universitaire de Poitiers, Laboratoire d'hématologie, Poitiers
| | - Carole Fleury
- Groupe Francophone d'Hématologie Cellulaire, Bron, France; Hôpital Avicenne AP-HP, Laboratoire d'hématologie, Bobigny
| | - Florence Blanc-Jouvan
- Groupe Francophone d'Hématologie Cellulaire, Bron, France; Centre Hospitalier Annecy Genevois, Laboratoire de biologie, Epagny Metz-Tessy
| | - Soraya Wuilleme
- Groupe Francophone d'Hématologie Cellulaire, Bron, France; Centre Hospitalier Universitaire de Nantes, Laboratoire d'Hématologie, Nantes
| | - Valérie Bardet
- Groupe Francophone d'Hématologie Cellulaire, Bron, France; Centre Hospitalier Universitaire Ambroise Paré AP-HP, Service d'Hématologie-Immunologie-Transfusion, Paris
| | - Thierry Fest
- Centre Hospitalier Universitaire de Rennes, Laboratoire d'Hématologie, Rennes, France; Université de Rennes 1, INSERM UMR 1236, Rennes
| | - Thierry Lamy
- Université de Rennes 1, INSERM UMR 1236, Rennes, France; Centre Hospitalier Universitaire de Rennes, Hématologie clinique, Rennes
| | - Mikael Roussel
- Centre Hospitalier Universitaire de Rennes, Laboratoire d'Hématologie, Rennes, France; Université de Rennes 1, INSERM UMR 1236, Rennes
| | - Mélanie Pannetier
- Centre Hospitalier Universitaire de Rennes, Laboratoire d'Hématologie, Rennes, France; Groupe Francophone d'Hématologie Cellulaire, Bron
| | - Cédric Pastoret
- Centre Hospitalier Universitaire de Rennes, Laboratoire d'Hématologie, Rennes, France; Université de Rennes 1, INSERM UMR 1236, Rennes.
| |
Collapse
|
2
|
Levy A, Guidez S, Debiais C, Princet I, Bouyer S, Dindinaud E, Delwail V, Systchenko T, Moya N, Gruchet C, Sabirou F, Bobin A, Gardeney H, Nsiala L, Cailly L, Olivier G, Motard C, Fleck E, Corby A, Roul C, Denis G, Dieval C, Leleu X, Tomowiak C. Waldenström macroglobulinemia and relationship to immune deficiency. Leuk Lymphoma 2021; 62:2665-2670. [PMID: 34085595 DOI: 10.1080/10428194.2021.1907379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Primary or secondary immune deficiency (ID) is a risk factor, although rare, to develop Waldenström macroglobulinemia (WM). We aimed to better understand the incidence of this occurrence in the real-life and the outcome of either entity. We conducted a review of 194 WM in the Poitou-Charentes registry and identified 7 (3.6%) with a prior history of ID. Across the 7 WM with ID, 4 progressed to active WM disease and required treatment for WM with a median time between WM diagnosis and the first treatment of 1.5 years (range 0-3). The median time from ID to WM occurrence was 8 years (1-18). WM could develop from ID, although a rare event. Our first action was to systematically decrease immunosuppression with long-term control of ID. Half of indolent WM remained indolent despite ID and for remaining WM none appeared of poor risk WM.
Collapse
Affiliation(s)
- Anthony Levy
- Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France
| | - Stéphanie Guidez
- Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France
| | - Céline Debiais
- Laboratoire d'Anatomie Pathologie, CHU, Poitiers, France
| | | | | | | | - Vincent Delwail
- Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France
| | - Thomas Systchenko
- Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France
| | - Niels Moya
- Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France
| | - Cécile Gruchet
- Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France
| | - Florence Sabirou
- Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France
| | - Arthur Bobin
- Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France
| | - Hélène Gardeney
- Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France
| | - Laly Nsiala
- Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France
| | - Laura Cailly
- Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France
| | | | | | | | - Anne Corby
- Service d'Onco-Hématologie, La Rochelle, France
| | | | | | | | - Xavier Leleu
- Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France
| | - Cécile Tomowiak
- Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France
| |
Collapse
|
3
|
Zalmaï L, Viailly PJ, Biichle S, Cheok M, Soret L, Angelot-Delettre F, Petrella T, Collonge-Rame MA, Seilles E, Geffroy S, Deconinck E, Daguindau E, Bouyer S, Dindinaud E, Baunin V, Le Garff-Tavernier M, Roos-Weil D, Wagner-Ballon O, Salaun V, Feuillard J, Brun S, Drenou B, Mayeur-Rousse C, Okamba P, Dorvaux V, Tichionni M, Rose J, Rubio MT, Jacob MC, Raggueneau V, Preudhomme C, Saas P, Ferrand C, Adotevi O, Roumier C, Jardin F, Garnache-Ottou F, Renosi F. Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape. Haematologica 2020; 106:3056-3066. [PMID: 33054115 PMCID: PMC8634182 DOI: 10.3324/haematol.2020.253740] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Indexed: 11/09/2022] Open
Abstract
Neoplasms involving plasmacytoid Dendritic Cells (pDCs) include Blastic pDC Neoplasms (BPDCN) and other pDC proliferations, where pDCs are associated with myeloid malignancies: most frequently Chronic MyeloMonocytic Leukemia (CMML) but also Acute Myeloid Leukemia (AML), hereafter named pDC-AML. We aimed to determine the reactive or neoplastic origin of pDCs in pDC-AML, and their link with the CD34+ blasts, monocytes or conventional DCs (cDCs) associated in the same sample, by phenotypic and molecular analyses (targeted NGS, 70 genes). We compared 15 pDC-AML at diagnosis with 21 BPDCN and 11 normal pDCs from healthy donors. CD45low CD34+ blasts were found in all cases (10-80% of medullar cells), associated with pDCs (4-36%), monocytes in 14 cases (1-10%) and cDCs (2 cases, 4.8-19%). pDCs in pDC-AML harbor a clearly different phenotype from BPDCN: CD4+ CD56- in 100% of cases, most frequently CD303+, CD304+ and CD34+; lower expression of cTCL1 and CD123 with isolated lymphoid markers (CD22/CD7/CD5) in some cases, suggesting a pre-pDC stage. In all cases, pDCs, monocytes and cDC are neoplastic since they harbor the same mutations as CD34+ blasts. RUNX1 is the most commonly mutated gene: detected in all AML with minimal differentiation (M0-AML) but not in the other cases. Despite low number of cases, the systematic association between M0-AML, RUNX1 mutations and an excess of pDC is puzzling. Further evaluation in a larger cohort is required to confirm RUNX1 mutations in pDC-AML with minimal differentiation and to investigate whether it represents a proliferation of blasts with macrophage and DC progenitor potential.
Collapse
Affiliation(s)
- Loria Zalmaï
- Service d'hématologie biologique, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris
| | | | - Sabeha Biichle
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon
| | - Meyling Cheok
- INSERM U837, CHRU Lille, IRCL Laboratoire d'Hématologie, Centre de Biologie Pathologie, Lille
| | - Lou Soret
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon
| | - Fanny Angelot-Delettre
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon
| | - Tony Petrella
- Department of Pathology, University of Montréal, Hôpital Maisonneuve-Rosemont, Montréal, QC
| | | | - Estelle Seilles
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon
| | - Sandrine Geffroy
- INSERM U837, CHRU Lille, IRCL Laboratoire d'Hématologie, Centre de Biologie Pathologie, Lille, France; Laboratoire d'Hématologie A, Centre de Biologie Pathologie, Boulevard du Pr Leclercq, 59037 Lille
| | | | | | - Sabrina Bouyer
- Service d'Hématologie biologique, CHU La Milétrie, Poitiers
| | | | - Victor Baunin
- Laboratoire du Groupe Hospitalier de La Rochelle-Ré-Aunis, CH de La Rochelle, La Rochelle
| | - Magali Le Garff-Tavernier
- Laboratoire d'Hématologie, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris
| | - Damien Roos-Weil
- Service d'Hématologie Clinique, Sorbonne Université, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris
| | - Orianne Wagner-Ballon
- Département d'Hématologie biologique, Hôpitaux Universitaires Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil
| | - Véronique Salaun
- Laboratoire d'Hématologie, CHU de Caen Normandie, Normandie Université, UNICAEN, Caen
| | - Jean Feuillard
- Laboratoire d'hématologie, CHU Dupuytren, avenue Martin Luther King, Limoges
| | - Sophie Brun
- Laboratoire d'Hématologie et Consultations d'Hématologie Biologique, Hôpital Universitaire Carémeau, Nîmes
| | - Bernard Drenou
- Service d'Hématologie, Groupe Hospitalier de la région Mulhouse Sud Alsace, Mulhouse
| | | | - Patricia Okamba
- Laboratoire d'hématologie et auto-immunité, Hôpital de Mercy, CHR de Metz-Thionville
| | | | | | - Johann Rose
- Laboratoire d'hématologie, CH du Mans, Le Mans
| | - Marie Thérèse Rubio
- Service Hématologie, CNRS UMR7365, Biopôle Université de Lorraine, CHRU Nancy, Vandœuvre-lès-Nancy
| | | | - Victoria Raggueneau
- Service de Biologie Médicale, Centre Hospitalier de Versailles A. Mignot, Le Chesnay
| | - Claude Preudhomme
- INSERM U837, CHRU Lille, IRCL Laboratoire d'Hématologie, Centre de Biologie Pathologie, Lille, France; Laboratoire d'Hématologie A, Centre de Biologie Pathologie, Boulevard du Pr Leclercq, 59037 Lille
| | - Philippe Saas
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon
| | - Christophe Ferrand
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon
| | - Olivier Adotevi
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon
| | - Christophe Roumier
- INSERM U837, CHRU Lille, IRCL Laboratoire d'Hématologie, Centre de Biologie Pathologie, Lille, France; Laboratoire d'Hématologie A, Centre de Biologie Pathologie, Boulevard du Pr Leclercq, 59037 Lille
| | | | - Francine Garnache-Ottou
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon.
| | - Florian Renosi
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon
| |
Collapse
|
4
|
Gallego Hernanz MP, Torregrosa Diaz JM, Sorel N, Bobin A, Dindinaud E, Bouyer S, Desmier D, Brizard F, Leleu X, Maillard N, Chomel JC. Long-term molecular remission in a patient with acute myeloid leukemia harboring a new NUP98-LEDGF rearrangement. Cancer Med 2019; 8:1765-1770. [PMID: 30848074 PMCID: PMC6488106 DOI: 10.1002/cam4.2051] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2018] [Revised: 01/21/2019] [Accepted: 02/03/2019] [Indexed: 12/17/2022] Open
Abstract
A large variety of molecular rearrangements of the NUP98 gene have been described in the past decades (n = 72), involving fusion partners coding for different transcription factors, chromatin modifying enzymes, as well as various cytosolic proteins. Here, we report the case of an AML-M2 patient with a variant NUP98-LEDGF/PSIP1 gene fusion (N9-L10). In this patient, three different NUP98-LEDGF fusion mRNAs were characterized due to alternative splicing in LEDGF exon 11. Targeted high-throughput sequencing revealed the presence of IDH1, SRSF2, and WT1 additional pathogenic mutations. To improve the therapeutic monitoring, quantification of NUP98-LEDGF mRNA by real-time PCR was developed. Because of poor response to conventional chemotherapy, allogeneic stem cell transplantation was performed, followed by 20 cycles of azacitidine-based preemptive treatment of relapse. More than 31 months after diagnosis, corresponding to 25 months post SCT and 4 months after the last cycle of azacytidine, the patient is in complete molecular remission (undetectable NUP98-LEDGF mRNA transcripts). This study highlights the considerable variability in breakpoint location within both NUP98 and LEDGF, associated with alternative splicing affecting LEDGF. It also emphasizes the need to fully characterize the breakpoints within the two genes and the identification of all fusion mRNAs, particularly for the development of a molecular monitoring assay. All these data seem critical for the optimal management of NUP98-LEDGF + hematological malignancies commonly associated with a poor prognosis.
Collapse
Affiliation(s)
| | | | - Nathalie Sorel
- CHU de Poitiers, Service de Cancérologie Biologique, Poitiers, France
| | - Arthur Bobin
- CHU de Poitiers, Service d'Oncologie Hématologique et Thérapie Cellulaire, Poitiers, France
| | - Elodie Dindinaud
- CHU de Poitiers, Service d'Hématologie Biologique, Poitiers, France
| | - Sabrina Bouyer
- CHU de Poitiers, Service d'Hématologie Biologique, Poitiers, France
| | - Deborah Desmier
- CHU de Poitiers, Service d'Oncologie Hématologique et Thérapie Cellulaire, Poitiers, France
| | | | - Xavier Leleu
- CHU de Poitiers, Service d'Oncologie Hématologique et Thérapie Cellulaire, Poitiers, France.,INSERM, CIC-P, Poitiers, France
| | - Natacha Maillard
- CHU de Poitiers, Service d'Oncologie Hématologique et Thérapie Cellulaire, Poitiers, France
| | | |
Collapse
|
5
|
Daix T, Guerin E, Tavernier E, Mercier E, Gissot V, Hérault O, Mira JP, Dumas F, Chapuis N, Guitton C, Béné MC, Quenot JP, Tissier C, Guy J, Piton G, Roggy A, Muller G, Legac É, de Prost N, Khellaf M, Wagner-Ballon O, Coudroy R, Dindinaud E, Uhel F, Roussel M, Lafon T, Jeannet R, Vargas F, Fleureau C, Roux M, Allou K, Vignon P, Feuillard J, François B. Multicentric Standardized Flow Cytometry Routine Assessment of Patients With Sepsis to Predict Clinical Worsening. Chest 2018; 154:617-627. [PMID: 29705219 DOI: 10.1016/j.chest.2018.03.058] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2017] [Revised: 02/21/2018] [Accepted: 03/19/2018] [Indexed: 10/17/2022] Open
Abstract
BACKGROUND In this study, we primarily sought to assess the ability of flow cytometry to predict early clinical deterioration and overall survival in patients with sepsis admitted in the ED and ICU. METHODS Patients admitted for community-acquired acute sepsis from 11 hospital centers were eligible. Early (day 7) and late (day 28) deaths were notified. Levels of CD64pos granulocytes, CD16pos monocytes, CD16dim immature granulocytes (IGs), and T and B lymphocytes were assessed by flow cytometry using an identical, cross-validated, robust, and simple consensus standardized protocol in each center. RESULTS Among 1,062 patients screened, 781 patients with confirmed sepsis were studied (age, 67 ± 48 years; Simplified Acute Physiology Score II, 36 ± 17; Sequential Organ Failure Assessment, 5 ± 4). Patients were divided into three groups (sepsis, severe sepsis, and septic shock) on day 0 and on day 2. On day 0, patients with sepsis exhibited increased levels of CD64pos granulocytes, CD16pos monocytes, and IGs with T-cell lymphopenia. Clinical severity was associated with higher percentages of IGs and deeper T-cell lymphopenia. IG percentages tended to be higher in patients whose clinical status worsened on day 2 (35.1 ± 35.6 vs 43.5 ± 35.2, P = .07). Increased IG percentages were also related to occurrence of new organ failures on day 2. Increased IG percentages, especially when associated with T-cell lymphopenia, were independently associated with early (P < .01) and late (P < .01) death. CONCLUSIONS Increased circulating IGs at the acute phase of sepsis are linked to clinical worsening, especially when associated with T-cell lymphopenia. Early flow cytometry could help clinicians to target patients at high risk of clinical deterioration. TRIAL REGISTRY ClinicalTrials.gov; No.: NCT01995448; URL: www.clinicaltrials.gov.
Collapse
Affiliation(s)
- Thomas Daix
- Réanimation Polyvalente, CHU Dupuytren, Limoges, France; Inserm CIC1435, CHU Dupuytren, Limoges, France
| | - Estelle Guerin
- Hématologie Biologique, CHU Dupuytren, Limoges, France; CNRS UMR 7276, Université de Limoges, Limoges, France
| | - Elsa Tavernier
- Inserm CIC1415, CHRU and Université François Rabelais, Tours, France
| | | | - Valérie Gissot
- Inserm CIC1415, CHRU and Université François Rabelais, Tours, France
| | | | - Jean-Paul Mira
- Réanimation Médicale Polyvalente, Hôpital Cochin, Assistance Publique des Hôpitaux de Paris, Paris, France
| | - Florence Dumas
- Urgences, Hôpital Cochin/Hôtel-Dieu, Assistance Publique des Hôpitaux de Paris and Inserm UMR 970, Université Paris Descartes, Paris, France
| | - Nicolas Chapuis
- Hématologie Biologique, Hôpital Cochin, Assistance Publique des Hôpitaux de Paris, Paris, France
| | | | - Marie C Béné
- Hématologie Biologique, CHU de Nantes, Nantes, France
| | - Jean-Pierre Quenot
- Réanimation Polyvalente, CHU François Mitterrand and Lipness Team, Centre de Recherche Inserm LNC-UMR1231 and LabExLipSTIC and Inserm CIC 1432, Epidémiologie Clinique, Université de Bourgogne, Dijon, France
| | | | - Julien Guy
- Hématologie Biologique, CHU de Dijon, Dijon, France
| | - Gaël Piton
- Réanimation Médicale, CHRU de Besançon, Université de Franche Comte, UFR SMP, EA3920, Besançon, France
| | - Anne Roggy
- Inserm UMR1098 and Laboratoire d'Immunologie, EFS BFC, Besançon, France
| | | | - Éric Legac
- Hématologie Biologique, CHR d'Orléans, Orléans, France
| | - Nicolas de Prost
- Réanimation Médicale, CHU Henri Mondor, Assistance Publique-Hôpitaux de Paris, DHU A-TVB, and Université Paris Est Créteil, Faculté de Médecine de Créteil, Groupe de Recherche CARMAS, Créteil, France
| | - Mehdi Khellaf
- Urgences, Assistance Publique-Hôpitaux de Paris, CHU Henri Mondor, Créteil, France
| | - Orianne Wagner-Ballon
- Hématologie et Immunologie Biologiques, Assistance Publique-Hôpitaux de Paris, CHU Henri Mondor and Université Paris-Est Créteil, Inserm UMR 955, Créteil, France
| | - Rémi Coudroy
- Réanimation Médicale, CHU de Poitiers, Poitiers, France
| | | | - Fabrice Uhel
- Réanimation Médicale and Inserm CIC1414, CHU de Rennes, and Inserm UMR 917, Université de Rennes, Rennes, France
| | - Mikaël Roussel
- Hématologie Biologique and Inserm UMR 1236, CHU Pontchaillou, Rennes, France
| | - Thomas Lafon
- Inserm CIC1435, CHU Dupuytren, Limoges, France; Urgences, CHU Dupuytren, Limoges, France
| | - Robin Jeannet
- Hématologie Biologique, CHU Dupuytren, Limoges, France
| | | | | | | | - Kaoutar Allou
- Hématologie Biologique, CHU de Bordeaux, Bordeaux, France
| | - Philippe Vignon
- Réanimation Polyvalente, CHU Dupuytren, Limoges, France; Inserm CIC1435, CHU Dupuytren, Limoges, France; Inserm UMR 1092, Université de Limoges, Limoges, France
| | - Jean Feuillard
- Hématologie Biologique, CHU Dupuytren, Limoges, France; CNRS UMR 7276, Université de Limoges, Limoges, France
| | - Bruno François
- Réanimation Polyvalente, CHU Dupuytren, Limoges, France; Inserm CIC1435, CHU Dupuytren, Limoges, France; Inserm UMR 1092, Université de Limoges, Limoges, France.
| | | |
Collapse
|